ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
PALATIN TECHS INC
8.53
0.0000
成交量:
- -
成交额:
- -
市值:
830.22万
市盈率:
- -
高:
8.53
开:
8.53
低:
8.53
收:
8.53
52周最高:
19.51
52周最低:
1.75
股本:
97.33万
流通股本:
- -
量比:
- -
换手率:
- -
股息:
- -
股息率:
- -
每股收益(LYR):
-2.0233
净资产收益率:
-378.67%
总资产收益率:
-70.26%
市净率:
0.72
市盈率(LYR):
-4.22
数据加载中...
总览
公司
新闻资讯
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻资讯
帕拉丁宣布口服MC4R激动剂PL7737在肥胖动物模型中取得积极临床前疗效数据
华尔街洞察
·
2025/07/15
Palatin公布口服MC4R激动剂PL7737在肥胖动物模型中积极临床前功效数据
华尔街洞察
·
2025/07/15
Palatin口服肥胖新药PL7737临床前数据亮眼,计划2026年启动I期试验
华尔街洞察
·
2025/07/15
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PTNT"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","market":"US","secType":"STK","nameCN":"PALATIN TECHS INC","latestPrice":8.53,"timestamp":1776788460000,"preClose":8.53,"halted":8,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":973300,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"04-21 12:21:00 EDT 延时","open":8.53,"high":8.53,"low":8.53,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1776801600000},"marketStatusCode":2,"adr":0,"exchange":"OTCQB","adjPreClose":8.53,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","floatShares":0,"roa":"-70.26%","roe":"-378.67%","lyrEps":-2.023264,"shares":973300,"dividePrice":0,"high":8.53,"amplitude":0,"preClose":8.53,"low":8.53,"week52Low":1.75,"pbRate":"0.72","psRate":"0.93","week52High":19.505,"institutionHeld":0.1111,"latestPrice":8.53,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":8.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTNT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"PTNT","oldSymbol":"PTNT","defaultRemindTime":1762957800000,"newSymbol":"PTN","exchange":"OTCQB","type":"symbolChange","dateTimestamp":1762923600000},{"market":"US","date":"2025-08-12","symbol":"PTNT","defaultRemindTime":1755005400000,"type":"split","dateTimestamp":1754971200000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTNT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTNT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1115580369","title":"帕拉丁宣布口服MC4R激动剂PL7737在肥胖动物模型中取得积极临床前疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1115580369","media":"华尔街洞察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115580369?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583435,"startTime":"0","endTime":"0","summary":"帕拉丁科技公司公布了其口服MC4R激动剂PL7737在肥胖动物模型中的积极临床前疗效数据。研究显示,PL7737与替西帕肽联用产生附加减肥效果,口服给药后在短短四天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药研究申请(IND),为后续开发铺路。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159628542","title":"Palatin公布口服MC4R激动剂PL7737在肥胖动物模型中积极临床前功效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159628542","media":"华尔街洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159628542?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 20:43","pubTimestamp":1752583426,"startTime":"0","endTime":"0","summary":"Palatin Technologies, Inc.今日宣布,其口服MC4R激动剂PL7737在肥胖动物模型中的临床前研究显示积极功效。研究结果表明,PL7737与tirzepatide联用可产生显著的加性减肥效果。效果惊人!口服PL7737在短短4天内即实现快速体重减轻。公司计划于2025年第四季度提交PL7737的新药临床试验申请(IND)。这一进展突显了该药物在肥胖治疗领域的潜力,为未来临床试验奠定基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105523922","title":"Palatin口服肥胖新药PL7737临床前数据亮眼,计划2026年启动I期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105523922","media":"华尔街洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105523922?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 19:33","pubTimestamp":1752579200,"startTime":"0","endTime":"0","summary":"生物医药企业Palatin Technologies近日公布其口服MC4R激动剂PL7737在肥胖症动物模型中取得突破性临床前数据。更值得注意的是,当PL7737与替西帕肽联用时,两者产生协同减重效应,减重幅度超越单一用药效果。根据研发规划,Palatin将于2025年第四季度向美国食品药品监督管理局提交PL7737的新药临床试验申请,预计2026年上半年公布首个人体试验数据。值得关注的是,PL7737已获得美国FDA授予的孤儿药资格认定,适应症为瘦素受体缺乏症相关肥胖。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PTNT\",params:#limit:6,delay:false,,,undefined,":[]}}